Life Science Incubator Selects New QuickFire Challenge Winners to Join JLABS @ NYC
纽约市，2018年6月21日 -ld乐动今天宣布的开幕式JLABS @纽约。30,000-square foot facility, located at the New York Genome Center in the heart of SoHo, is a collaboration between Johnson & Johnson Innovation, New York State and the New York Genome Center. JLABS @ NYC can accommodate up to 30 biotech, pharmaceutical, medical device, consumer and health tech companies and opens with 26 resident companies, including the four winners of the JLABS @ NYC QuickFire Challenge.
“约翰逊和约翰逊在纽约拥有深刻的企业家根源，我们很高兴看到我们在这个丰富的生态系统中应用了我们独特的JLABS模型，促进了创造具有改变人类健康轨迹的新的医疗保健创新，”保罗说Stoffels, M.D., Chief Scientific Officer, Johnson & Johnson. “Expanding our JLABS network to NYC will link entrepreneurs around the region with Johnson & Johnson Innovation experts, allowing some of the brightest minds in healthcare to work collaboratively in a shared space.”
“This new 21st century incubator supports our efforts to boost economic growth by investing in cutting-edge research and technologies that advance human health,” Governor Cuomo said. “By investing in JLABS @ NYC, we’re connecting early-stage companies with the tools, resources, and networks to succeed while enhancing the life sciences industry and fostering job growth across New York.”
In addition to opening the new site, JLABS @ NYC announced the four winners of the JLABS @ NYC QuickFire Challenge. The winners of the QuickFire Challenge receive one year of residence in JLABS @ NYC, providing access to a bench, workstation and the global JLABS community. The four winners are: Lab11 Therapeutics LLC; Manhattan Biosolutions; Sapience Therapeutics, Inc.; and Mobile Sense Technologies, Inc.
“For too long, patients and consumers have not fully benefitted from the incredible genius throughout the world. NYC and its environs are home to some of the greatest minds in scientific innovation, whose skills and their spirit have so much to offer,” said Melinda Richter, Global Head of JLABS at Johnson & Johnson Innovation. “JLABS provides those innovators the environment they need to deliver life-enhancing, life-saving solutions to the people who need them. By opening up vital industry connections, entrepreneurial programs and a capital-efficient, flexible platform to help alleviate the cost burden that typically slows or kills innovation, we know NYC will light up our world.”
“纽约基因组中心荣获与约翰逊和约翰逊创新和纽约国家的合作伙伴，将Jlabs网络带到纽约，进一步加强生命科学部门，”尼基州尼斯·米尔·默尔（Nygc总裁兼COO）表示。“纽约委员会努力将基因组研究转化为人类疾病的新诊断工具和治疗，这与JLABS的愿景完全和谐，提供了支持一个平台，以支持新兴公司将科学发现转变为突破医疗保健产品。我们很高兴看到Jlabs @ NYC的未来发展，我们感谢总督的领导力和支持在纽约的生活科学基础设施方面。“
jlabs.facilities have incubated more than 370 companies to date, advancing biotech, pharmaceutical, medical device, consumer and health tech programs. JLABS @ NYC will follow the same no-strings-attached approach across all JLABS locations: San Diego; San Francisco; South San Francisco; Boston; Lowell, MA; Houston; Toronto; Beerse, Belgium; and Shanghai.
The following companies are the first to be selected as residents of JLABS @ NYC:
A2A药物
A2A Pharmaceuticals的使命是利用包括AI在内的专有计算系统，以加速新型药物替代品的发展，危及癌症，细菌感染和肌营养不良症。
AMABiotics
AMABiotics is a biopharmaceutical company that develops innovative microbiome-derived medicines to fight age-related diseases. Its research focuses on Gut-Brain axis. AMABiotics’ lead candidate is AMA-101, a potential first-in-class therapy in Parkinson’s disease.
Certa Dose
Certa Dose offers an intuitive system that uses color confirmation to deliver accurate dosing.
Chimeron Bio
Chimeron Bio正在开发一种新的RNA递送平台技术，其应用在包括肿瘤，传染病和稀有遗传疾病的几种治疗区域。
Curie Co.
Curie Co. engineers biopolymers and enzymes to replace petrochemical-based ingredients in the personal care and consumer healthcare industry that have been banned in the U.S. and E.U. by the FDA and EC, respectively.
envisagenics.
envisagenics.’ AI platform analyzes RNA-sequencing data to develop cures for diseases caused by splicing errors.
EpiBone
EpiBone is a revolutionary biotech company, whose regenerative technology will give patients a way to help heal themselves by growing living bone and cartilage grafts that are made from their own cells.
Epigencare.
Epigencare测量当前的皮肤质量状态，并在市场上与基于表观遗传标记和区间技术的直接消费的护肤试验相匹配型材。
f
fautomates the creation of globally accessible, custom-fit, patient-specific medical devices across medical braces, orthosis, prosthesis, and medical implants just from patients' photos and medical images using Fited's end-to-end, digital, AI-driven design platform that learns the skills of the craftsman who manually create these devices today.
人类微生物研究所
人类微生物学院专注于癌症，神经变性和自身免疫 - 未开发的细菌病原体和噬菌体（Phagobiota）作为新的治疗目标，以及新的AI预防算法。
Health Care Originals
Health Care Originals is an everyday digital health system with a proprietary wearable that provides early warning of flare ups in respiratory illnesses, e.g., asthma, COPD, as early warning signs are difficult to notice resulting in medical attention, disruption and even lifelong issues that could have been avoided.
Lab11 Therapeutics LLC.
Lab11 Therapeutics LLC是一家启动生物技术公司，开发宿主靶向，小分子，广谱，抗病毒药物，第一个患有流感病毒的症状。
Legomics
Legomics’ chemistry enables the building of a desktop gene writer machine.
Lymph/Axis
Lymph/Axis is the very first percutaneous lymphatic access platform to aspirate and infuse lymphocytes, dendritic cells, plasma fluid, extracellular components, and drug compounds.
曼哈顿Biosolutions，Inc
曼哈顿生物化的铅平台基于安全，减毒的BCG细菌靶向突变的癌症驾驶基因，诱导先天和适应性癌症特异性免疫应答。
MedoPad
Medopad是一个CE批准的患者监控软件解决方案，包括模块化护理监控工具，患者数据跟踪和患者信息工具，以提供易于使用的尚未使用的全整体数字健康解决方案，可以跨垂直和治疗条件应用。
Mobile Sense Technologies, Inc.
Mobile Sense is a digital health technology company providing foundational technology enabling off-the-chest medical wearables for long-term management of cardiac arrhythmias.
Mymee
Mymee's Digital Therapeutics program reverses the symptoms of chronic autoimmune disease through data analytics and health coaching, reducing or eliminating the need for expensive drugs.
Nanochon
Nanochon is focused on creating a new type of cartilage implant that can replace lost cartilage on a short-term basis and can fuse with the body on a longer term, improving patient outcomes.
纳瓦
Nanowear’s connected-self technology and analytics platform for diagnostics and chronic disease management utilizes first-of-its-kind, FDA-cleared, cloth-based nanosensors (Nanowear’s first product, SimpleSense, is an undergarment for remote alert detection in Heart Failure).
Redpin
Redpin's breakthrough technology platforms enable targeted regulation of neuronal activity in the brain to achieve treatment and control of CNS circuit and other disorders.
Repairogen Corp.
Repairogen Corp. develops potent, robust, naturally-derived, small-molecule active ingredients for skincare that provide powerful anti-aging effects by enhancing DNA repair activity in skin cells.
Savor Health
Savor Health addresses the nutritional issues of cancer patients through an AI-based care platform in order to improve adherence, increase engagement, reduce health spending and empower patients.
Sapience Therapeutics，Inc。
Sapience Therapeutics，Inc。, is a biotechnology company focused on discovering and developing peptide-based therapeutics that inhibit oncogenic and immune-modulatory protein:protein interactions.
Veta Health
Veta Health是一家人口卫生公司，提供一个技术平台，可在任何时候使患者生成的数据临床有意义，能够在任何时候都能进行个性化的基于协议的护理。
All JLABS locations are accepting applications from biotech, pharmaceutical, medical device, consumer and health tech companies. To learn more, visit//www.2574design.com/。
关于约翰逊和约翰逊的创新
ld乐动Johnson＆Johnson Innovation LLC专注于加快全球创新的所有阶段，并在企业家和约翰逊和约翰逊的全球医疗业务之间形成合作。约翰逊＆约翰逊的创新为科学家，企业家和新兴公司提供一站式地访问科技专家，他们可以促进约翰逊和约翰逊的制药，医疗设备和消费公司的合作。根据Johnson＆Johnson创新伞的企业，我们通过我们的区域创新中心与创新者联系;约翰逊和约翰逊创新|jlabs.; Johnson & Johnson Innovation – JJDC, Inc.; and our business development teams to create customized deals and novel collaborations that speed development of innovations to solve unmet needs in patients. JLABS provides the laboratories, expertise, education, tools and resources needed to help life science startups thrive, all with no strings attached. A Johnson & Johnson Innovation Center for Device Innovation at the Texas Medical Center (CDI @ TMC) has been established to accelerate the development of medical devices. For more information about Johnson & Johnson Innovation, please visit:www.jnjinnovation.com。
关于约翰逊和约翰逊的创新, JLABS
约翰逊和约翰逊创新|jlabs.(JLABS) is a global network of open innovation ecosystems, enabling and empowering innovators across a broad healthcare spectrum including pharmaceutical, medical device, consumer and health tech sectors to create and accelerate the delivery of life-saving, life-enhancing health and wellness solutions to patients around the world. JLABS achieves this by providing the optimal environment for emerging companies to catalyze growth and optimize their research and development by opening them to vital industry connections, delivering entrepreneurial programs and providing a capital-efficient, flexible platform where they can transform the scientific discoveries of today into the breakthrough healthcare solutions of tomorrow. At JLABS, we value great ideas and are passionate about removing obstacles to success to help innovators unleash the potential of their early scientific discoveries. JLABS is a no-strings-attached model, which means entrepreneurs are free to develop their science while holding on to their intellectual property. JLABS also produces campaigns to seek out the best science called QuickFire Challenges. For more information, visitwww.www.2574design.com.或遵循@jlabs。
# # #
媒体联系人：
约翰逊和约翰逊创新
伊林沃尔什
（857）253-9554
